Ascendiant Capital Markets Forecasts SINT Q1 Earnings

Sintx Technologies, Inc. (NASDAQ:SINT) – Analysts at Ascendiant Capital Markets cut their Q1 2026 earnings per share (EPS) estimates for Sintx Technologies in a note issued to investors on Tuesday, April 7th. Ascendiant Capital Markets analyst E. Woo now expects that the company will earn ($0.55) per share for the quarter, down from their prior forecast of ($0.54). Ascendiant Capital Markets has a “Buy” rating and a $12.00 price objective on the stock. Ascendiant Capital Markets also issued estimates for Sintx Technologies’ Q2 2026 earnings at ($0.56) EPS and FY2026 earnings at ($2.16) EPS.

Several other brokerages have also weighed in on SINT. HC Wainwright started coverage on Sintx Technologies in a report on Monday. They issued a “buy” rating and a $10.00 price objective for the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Sintx Technologies in a report on Thursday, January 22nd. Two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $11.00.

Sintx Technologies Stock Performance

Shares of SINT stock opened at $2.74 on Wednesday. Sintx Technologies has a 1 year low of $1.71 and a 1 year high of $6.78. The business’s fifty day moving average is $2.76 and its 200-day moving average is $3.35. The stock has a market cap of $11.29 million, a PE ratio of -0.48 and a beta of 0.66.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in SINT. Geode Capital Management LLC boosted its holdings in shares of Sintx Technologies by 33.5% in the second quarter. Geode Capital Management LLC now owns 15,339 shares of the company’s stock worth $49,000 after buying an additional 3,848 shares during the period. Veracity Capital LLC increased its position in shares of Sintx Technologies by 10.3% in the third quarter. Veracity Capital LLC now owns 79,928 shares of the company’s stock worth $327,000 after acquiring an additional 7,464 shares in the last quarter. Finally, Virtus Wealth Solutions LLC acquired a new stake in shares of Sintx Technologies during the third quarter valued at approximately $388,000. Institutional investors and hedge funds own 18.38% of the company’s stock.

Sintx Technologies News Roundup

Here are the key news stories impacting Sintx Technologies this week:

• Positive Sentiment: HC Wainwright initiated coverage with a “Buy” and a $10 price target, publishing multi‑year estimates that project profitability by FY2029–FY2030 — a positive catalyst that can attract growth‑oriented investors. HC Wainwright Initiates Coverage on Sintx Technologies
• Positive Sentiment: Ascendiant Capital Markets maintains a “Buy” rating with a $12 target, supporting follow‑through demand from investors who track sell‑side coverage.
• Neutral Sentiment: Analysts’ models show a long runway: HC Wainwright forecasts meaningful losses through FY2026–FY2028 before EPS turns positive in FY2029–FY2030 — this signals high upside if commercial/clinical execution meets milestones but also longer timing risk.
• Negative Sentiment: Ascendiant trimmed near‑term EPS estimates slightly (Q1/Q2 2026 and FY2026 cuts), and both firms expect sizable losses in FY2026–FY2027 — near‑term earnings weakness increases downside risk and keeps the stock speculative.
• Negative Sentiment: Small market cap, negative trailing P/E, and the stock trading below its 200‑day moving average elevate volatility and downside risk for investors who prioritize liquidity and technical support.

Sintx Technologies Company Profile

Sintx Technologies, Inc (NASDAQ: SINT) is a medical materials company specializing in the development and manufacture of silicon nitride-based biomaterials for surgical and implantable medical devices. Its proprietary silicon nitride ceramic combines mechanical strength, biocompatibility and intrinsic antimicrobial properties, positioning it as an alternative to traditional metal and polymer implant materials. Sintx’s primary focus is on applications in spinal fusion, trauma fixation and dental implantology, where device performance and long-term biological response are critical.

The company’s core product offerings include silicon nitride powders for advanced implant fabrication and finished implantable components designed for interbody spinal fusion cages, spinal fixation hardware and trauma plates and screws.